Korean J Fam Pract. 2018; 8(5): 775-777  https://doi.org/10.21215/kjfp.2018.8.5.775
Utility of Serum Cytokine Fragment 21-1 on Diagnosis of Lung Cancer
Dami You1, Dong Su Kang1, Eui Won Kim1, Doo Wan Cho1, Na Young Park2, Hyo Rim Son1,*
1Department of Family Medicine, Gwangju Veterans Hospital, Gwangju; 2Department of Family Medicine, Namwon Medical Center, Namwon, Korea
Hyo Rim Son
Tel: +82-62-602-6267, Fax: +82-62-602-6982
E-mail: damiu@hanmail.net
ORCID: http://orcid.org/0000-0003-2239-1914
Received: March 15, 2017; Revised: August 30, 2017; Accepted: September 6, 2017; Published online: October 20, 2018.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Cytokine fragment (Cyfra) 21-1 is a segment of cytokeratin 19 present in the cytoplasm of epithelial tumor cells, and is used as a tumor marker because its serum concentration is measured as it is released into the blood upon destruction of epithelial tumor cells. The aim of this study was to compare the diagnostic efficacy of Cyfra 21-1 in the serum of patients with other lung diseases, such as lung cancer, other cancers, pneumonia, and other diseases.
Methods: From March 1, 2016 to November 30, 2016, 43 patients (15 patients with lung cancer, 5 patients with other cancers except lung cancer, 8 patients with respiratory diseases, such as pneumonia, and 15 patients who were hospitalized for other pulmonary diseases) were admitted to the hospice and family medicine departments of Gwangju Veterans Hospital and enrolled in this study. The correlation between variables, such as gender, age, history of tuberculosis, and smoking history were analyzed using crossover, linear regression, and multiple regression analyses.
Results: In the lung cancer group, the value of Cyfra 21-1 in patients with lung cancer was statistically significant with a significance of 0.000. The effects of gender, age, smoking history, and history of tuberculosis on Cyfra 21-1 were not statistically significant.
Conclusion: These results suggest that Cyfra 21-1 is a useful marker for the diagnosis of lung cancer.
Keywords: Lung Cancer; Pulmonary Diseases; Tuberculosis; Tumor Marker; Cytokine Fragment 21-1
  1. Ministry of Health and Welfare. Cancer registration statistics, Health section, 2017. Daejeon: National Statistical Office; 2017 Dec. 95 p.
  2. Park SY, Lee JG, Kim J, Park Y, Lee SK, Bae MK, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer 2013 ;79: 156-60.
    Pubmed CrossRef
  3. Stieber P, Bodenmüller H, Banauch D, Hasholzner U, Dessauer A, OfenlochHähnle B, et al. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem 1993; 26: 301-4.
  4. Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, et al. CYFRA 21-1 as a prognostic and predictive marker in advanced non-smal-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 2012; 7: 649-54.
    Pubmed KoreaMed CrossRef
  5. Lee S, Lee CY, Kim DJ, Hong DJ, Lee JG, Chung KY. Pathologic correlation of serum carcinoembryonic antigen and cytokeratin 19 fragment in resected nonsmall cell lung cancer. Korean J Thorac Cardiovasc Surg 2013; 46:192-6.
    Pubmed KoreaMed CrossRef
  6. Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, et al. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma:a retrospective study. BMC Cancer 2013; 13: 354.
    Pubmed KoreaMed CrossRef
  7. Chen Q, Ge F, Cui W, Wang F, Yang Z, Guo Y, et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta 2013; 419: 57-61.
    Pubmed CrossRef
  8. Park HD, Jeong HS, Park JS, Lim SH, Lee EJ, Yun JW, et al. Usefulness of cyfra 21-1 as a tumor marker of lung cancer. Korean J Med 2002; 62: 415-21.
  9. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
  10. Niklinski J, Furman M, Rapellino M, Chyczewski L, Laudanski J, Oliaro A, et al. CYFRA 21-1 determination in patients with non-small cell lung cancer:clinical utility for the detection of recurrences. J Cardiovasc Surg (Torino) 1995; 36: 501-4.
  11. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-6.
  12. Jung M, Kim SH, Hong S, Kang YA, Kim SK, Chang J, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J 2012; 53: 931-9.
    Pubmed KoreaMed CrossRef
  13. Yoon HD, Kim KD, Chung JH, Lee HW, Lee KH, Lee HW, et al. Diagnostic value of serum CYFRA 21-1 in lung cancer. Tuberc Respir Dis 1995; 42:149-55.

This Article

Author ORCID Information

Social Network Service